DDInter108 DDInter105
Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FDA on December 28, 2012.
A plasma alpha 2 glycoprotein that accounts for the major antithrombin activity of normal plasma and also inhibits several other enzymes. It is a member of the serpin superfamily.
Apixaban {u} (Compound) binds {v} (Gene) CYP2C8
Apixaban {u} (Compound) causes {v} (Side Effect) Incision site haemorrhage
Apixaban {u} may cause a minor interaction that can limit clinical effects when taken with {v} Capsicum
Apixaban {u} may cause a minor interaction that can limit clinical effects when taken with {v} Modafinil
Apixaban {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Duloxetine
Apixaban {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eliglustat
Apixaban {u} may lead to a major life threatening interaction when taken with {v} Desirudin
Apixaban {u} may lead to a major life threatening interaction when taken with {v} Trastuzumab emtansine
Apixaban (Compound) binds CYP2C8 (Gene)
Apixaban (Compound) causes Incision site haemorrhage (Side Effect)
Apixaban may cause a minor interaction that can limit clinical effects when taken with Capsicum
Apixaban may cause a minor interaction that can limit clinical effects when taken with Modafinil
Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Duloxetine
Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Apixaban may lead to a major life threatening interaction when taken with Desirudin
Apixaban may lead to a major life threatening interaction when taken with Trastuzumab emtansine